News

Vancomycin 125 mg once or twice daily might help patients who are at the highest risk for recurrent infection.

Regardless of the number of previous treatment failures or emergence of the single or double RAVs after the first treatment failure all patients achieved SVR at 12 weeks on the regimen.

UK investigators conducted the first large study seeking to understand whether the same or different genes explain why some people experience more severe asthma symptoms.

The analyzer tests samples with an infrared spectroscopy system, providing measurements of various nutrients. It is intended for use by trained personnel in clinical settings.

A series of newly marketed therapies—from cannabidiol to smartwatches—showed where the future of epilepsy care may grow.

New options for BPDCN and PNH provide patients alternatives to more burdensome standard-of-care treatment.

A step-by-step look into how Arctic Surgery Group treats postoperative patients.

How an Alaska-based surgical group responded to the opioid epidemic with a multi-step strategy of pain management care.

A more multidisciplinary, collaborative care effort for these patients can result in more active monitoring and productive clinical care.

There were no significant differences among tardive syndrome patients and healthy controls in either resting motor function or active motor function, and both group's symptoms improved with raised intensity.

A Canadian study finds patients like using an app meant to work alongside at-home HIV tests and ensure patients are quickly linked with care.

Recent antibiotic use and hospitalization status were some of the risk factors for C difficile infection.

With no distinctive definition for what constitutes asthma-COPD overlap, clinicians are advising both diseases become diagnosed and treated differently.

Evidence for dietary, immunological, surgical, and other emerging treatments for pediatric refractory status epilepticus is found to be mostly anecdotal.

The FDA has approved pembrolizumab for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

The patients with C difficile were more often older, in the hospital longer, and had greater total costs.

New research finds foreign-born black women aren’t benefiting from public health advances in HIV at the same rates.

The community-based program intent on improving black men's blood pressure care will revamp its practice headed into 2019.

The FDA has approved Shire’s prucalopride (Motegrity) for the treatment of chronic idiopathic constipation (CIC).

Mechanistic studies examining human milk bioactives and their impact on lung health and asthma development are beginning to emerge. What more needs to be found?

Over the past 5 years, the US healthcare system has gradually become a victim of its own success.

A form of artificial intelligence could 1 day be a diagnostic tool for disorders like epilepsy.

Preventative medicine dominated the focus for C difficile treatment; however, a new reactive therapy also emerged.

New research helps explain why young gay black men have much higher rates of HIV despite also having much lower rates of risky behavior.

Children often develop food allergies prior to developing asthma, and the former condition is associated with a greater risk of the latter condition in later life.

After successful trials in animal models, researchers say they will soon launch clinical trials of an eye drop to treat age-related macular degeneration.

New research shows the majority of young people get HCV through drug use, but also finds liver disease progresses at the same pace regardless of age at diagnosis.

After nearly a year of therapy, 84.5% of patients treated with guselkumab achieved at least 90% severity index improvement, compared to 70% of those treated with secukinumab.

The therapy is indicated for ITP patients aged 1 year and older who have been diagnosed for at least 6 months, and have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

The FDA has approved romiplostim for the treatment of pediatric patients with immune thrombocytopenia (ITP).